A number of bile acid-based therapies, including FXR agonists, TGR5 agonists, bile acid transporter inhibitors, and others, have been developed and show promise for the treatment of non-alcoholic steatohepatitis [144]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.